Navigation Links
Women & Infants participating in study of treatment of common viral infection in pregnancy
Date:4/23/2012

Women & Infants Hospital of Rhode Island, through its participation in the Maternal-Fetal Medicine Units Network, has been named the lead center in a 14-site, $25 million study of cytomegalovirus (CMV), the most common infection during pregnancy. Researchers want to see whether giving recently infected pregnant women antibodies against CMV lowers the rate of CMV infection in their babies. This study is funded by the National Institute of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Principal investigator is Brenna Anderson, MD, of the Division of Maternal-Fetal Medicine and the Integrated Program for High-Risk Pregnancy at Women & Infants Hospital and assistant professor of obstetrics and gynecology at The Warren Alpert Medical School of Brown University.

Dr. Anderson said, "Each year in the US, CMV infection affects more infants than Down syndrome and spina bifida combined. Yet until recently we have not been able to efficiently screen for it. Now that we can, we are in a position to test promising treatments."

CMV is a common virus spread like a cold or the flu. Approximately 1% of pregnant women will be infected with CMV for the first time, which results in a 40% chance that the fetus will also be infected. Fetuses who are infected with CMV are more likely to be born earlier than expected and develop problems such as hearing loss and learning disabilities.

The study will screen more than 150,000 women for evidence of primary CMV infection and randomize those who are positive to CMV hyperimmune globulin or placebo in an effort to decrease the risk of congenital CMV. This will be among the biggest trials done by the Maternal-Fetal Medicine Units Network in their 20+ year history.

Pregnant women with a single fetus who have not yet reached the 24th week of pregnancy are eligible to participate in this study. A small amount of additional blood will be taken from participants in conjunction with routinely scheduled prenatal blood testing (that is, the screening will minimize needle sticks).

"Screening will show a woman if she has been infected with CMV while pregnant, and she may then be eligible for the randomized treatment trial," said Dr. Anderson.


'/>"/>
Contact: Amy Blustein
ablustein@wihri.org
401-681-2822
Women & Infants Hospital
Source:Eurekalert

Related biology news :

1. Women do not recover their muscle strength as fast as men
2. Brown University and Women & Infants Hospital expand national childrens study to Bristol County
3. Vitamin K does not stem BMD decline in postmenopausal women with osteopenia
4. Study: Elderly Women can increase strength but still risk falls
5. Pregnant women consuming flaxseed oil have high risk of premature birth
6. 17th Annual Congress on Womens Health convenes
7. Pregnant women with asthma can be more confident about some medicines
8. Men are red, women are green, Brown researcher finds
9. Statin warning for pregnant women
10. Long-term use of diabetes drugs by women significantly increases risk of fractures
11. Women double fruit, veggie intake with switch to Mediterranean diet plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/15/2016)... BADEN-BADEN, Germany , December 15, 2016 /PRNewswire/ ... services provider, today announced an agreement with NuData Security, ... join forces. The partnership will enable clients to focus on ... with local data protection regulation. ... In order to provide a one-stop ...
(Date:12/15/2016)... Dec. 15, 2016 Advancements in ... health wellness and wellbeing (HWW), and security ... three new passenger vehicles begin to feature ... recognition, heart beat monitoring, brain wave monitoring, ... monitoring, and pulse detection. These will be ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... a global Phase 2b induction study in ulcerative ... alpha4beta7 integrin. The aim of this randomized, double-blind, ... safety/tolerability and efficacy of PTG-100 in approximately 240 ... active disease. "We are very ...
(Date:1/16/2017)... N.Y. , Jan. 16, 2017   Valentin ... J. Tracey, MD , president and CEO of ... Health, completed an analysis of how the nervous system ... identify and develop bioelectronic medicine devices to ... in Nature Neuroscience . The paper ...
(Date:1/14/2017)... Diego, CA (PRWEB) , ... January 14, 2017 ... ... of Proximo™, a new service providing complete end-to-end genome assemblies to researchers around ... complete genomes eliminates a major obstacle in answering a wide range of scientific ...
(Date:1/13/2017)... 13, 2017 Research and Markets has announced the ... offering. ... market to grow at a CAGR of 16.83% during the period 2017-2021. ... prospects of the global biopolymers market for 2017-2021. To calculate the market ... of biopolymer products. The report also includes a a discussion of the ...
Breaking Biology Technology: